Study Objective:
  • The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. 

Key Requirements:
  • Be ages 50 to 87 years old

  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease

  • Have a gradual change in memory for six months or more

  • Have a family member or loved one who can be available as a study partner during the entire study

  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Study Information:
  • All study medication and all study-related exams at no cost

  • Compensation for time and travel 

  • Transportation can be arranged at no cost to you 


Mild to Moderate Alzheimers Disease

Poster July2022.JPG

Click the link below and fill out the attached form to see if you qualify today!